Author

Yuxin Liang

GenentechORCID 0000-0001-6872-5030Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Yuxin Liang2 papers · Genentech

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Synthetic Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Organism:Drosophila· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1

Frequent Co-Authors

Anwesha DeyiD· 2 shared Sayantanee PauliD· 2 shared Thijs J. HagenbeekiD· 2 shared Zora D. ModrusaniD· 2 shared Alan AshworthiD· 1 shared Alissa D. GuarnacciaiD· 1 shared Ana Xavier‐MagalhãesiD· 1 shared Bence DánieliD· 1 shared

Activity by Year

2023-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Anwesha DeyORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Synthetic BiologyNanomedicine Nanotechnology Biology and MedicinePeer-reviewedNov 28, 2025

Enhanced cellular and transdermal delivery of the modified chromatin using gH625 cell-penetrating peptide

Xinghan Zhang, Yuxin Liang, Francesco Zonta, Jeong Hyeon Park

This study demonstrates that gH625-modified chromatin enhances transdermal delivery of EGF, showing comparable biological activity to free EGF in cells.

DOI 10.1016/j.nano.2025.102884

mouseprotein structure

𝕏 PostBluesky

Cancer BiologybioRxivPreprintFeb 20, 2025

Promoter-centric gene regulation in drug-resistant cancer

Vasumathi Kameswaran, Sayantanee Paul, Daniel X. Le…·Bence Dániel

This study shows that mesothelioma cells develop drug resistance by reverting to a promoter-centric gene regulation mechanism when treated with a TEAD inhibitor.

2 citations

𝕏 PostBluesky

Cancer BiologybioRxivPreprintOct 3, 2023

Targeting the Hippo pathway in cancers via ubiquitination dependent TEAD degradation

Trang H. Pham, Kanika Bajaj Pahuja, Thijs J. Hagenbeek…·Anwesha Dey

This study identifies RNF146 as an E3 ubiquitin ligase that degrades TEAD proteins via the proteasome, showing that pharmacological induction of TEAD ubiquitination can suppress YAP/TAZ-driven cancer growth.

DOI 10.1101/2023.10.03.560675

Drosophilaproteomics

𝕏 PostBluesky